Application of AT1-angiotensin II receptor blocker valsartan in clinical practice

Kardiologiya

Volumn 51, Issue 8, 2011, Pages 77-84

  Maximov, M L ^a   Mochkin, I A ^a   Starodubtsev, A K ^a  

^a I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR; DRUG DERIVATIVE; TETRAZOLE DERIVATIVE; VALINE; VALSARTAN;

BLOOD PRESSURE; DRUG EFFECT; DRUG MONITORING; ELECTROLYTE BALANCE; HEART FAILURE; HUMAN; HYPERTENSION; KIDNEY FAILURE; METABOLISM; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BLOOD PRESSURE; DRUG MONITORING; HEART FAILURE; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, ANGIOTENSIN; RENAL INSUFFICIENCY; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES; VALINE; WATER-ELECTROLYTE BALANCE;

EID: 80555125035     PISSN: 00229040     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (84)

1. Bissessor N., White H. Valsartan in the treatment of heart failure or left ventricular dysfunction after myocardial infarction. Vasc Health Risk Manag 2007;3:425-430.
2. Ortlepp J. P., Vosberg H. P., Reith S. et al. Genetic polymorphisms in the renin-angiotensin-aldosterone system associated with expression of left ventricular hypertrophy in hypertrophic cardiomyopathy: a study of five polymorphic genes in a family with a disease causing mutation in the myosin binding protein C gene. Heart 2002;87:270-275.
3. Griendling K. K., Murphy T. J., Alexander R. W. Molecular biology of the renin-angiotensin system. Circulation 1993;87:1816-1828.
4. Unger T. Blood pressure lowering and renin-angiotensin system blockade. J Hypertens 2003;21, Suppl 6:S3-S7.
5. Erdos E. G. Angiotensin I converting enzyme and the changes in our concepts through the years. Hypertension 1990;16:363-370.
6. Perazella M. A., Setaro J. F. Renin-angiotensinaldosterone systejn: fundamental aspects and clinical implications in renal and cardiovascular disorders. J Nucl Cardiol 2003;10:184-194.
7. Batenburg W. W., Krop M., Garrelds I. M. et al. Prorenin is the endogenous agonist of the (pro) renin receptor. Binding kinetics of rennin and prorenin in rat vascular smooth muscle cells overexpressing the human (pro) renin receptor. J Hypertens 2007;25:2441-2453.
8. Kobori H., Nangaku M., Navar L. G., Nishiyama A. The Intrarenal Renin-Angiotensin System: From Physiology to the Pathobiology of Hypertension and Kidney Disease. Pharmacol Rev 2007;59:251-287.
9. Paul M., Mehr A. P., Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev 2006;86:747-803.
10. Gasparo M., Catt K. J., Inagami T. et al. International Union of Pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000;52:415-472.
11. Goodfriend T. L., Oparil S., Weber M. Angiotensins: actions and receptors. In Hypertension 2000;2:11-13.
12. Goodfriend T. L., Elliott M. E., Catt K. J. Angiotensin receptors and their antagonists. N Engl J Med 1996;334:1649-1654.
13. Brugts J. J., den Uil C. A., Danser A. H. J., Boersma E. The Renin-Angiotensin-Aldosterone System: Approaches to Guide Angiotensin-Converting Enzyme Inhibition in Patients with Coronary Artery Disease. Cardiology 2009;112:303-312.
14. Weber MA. Angiotensin II receptor blockers. In Hypertension 2000;377-378.
15. Weir M. R. Opportunities for cardiovascular risk reduction with angiotensin II receptor blockers. Cur Hypertens Report 2002;4:333-335.
16. Burnier M., Maillard M. The comparative pharmacology of angiotensin II receptor antagonists. Blood Press 2001;10(Suppl. 1):6-11.
17. Waldmeier F, Flesch G., Muller P. et al. Xenobiotica 1997;27:59-71.
18. Lacourciere Y. et al. Antihypertensive efficacy and tolerability of two fixeddose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, double-blind, parallel-group trial Clin Ther 2005;27:1013-1021.
19. Malacca E., Vari N., Capuano V. et al. A randomized, double-blind, activecontrolled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study. Clin Ther 2003;25:2765-2780.
20. Destro M., Scabrosetti R., Vanasia A., Mugellini A. Comparative efficacy of valsartan and olmesartan in mild-to-moderate hypertension: results of 24-hour ambulatory blood pressure monitoring. Adv Ther 2005;22:32-43.
21. Abts M., Claus V., Latasler M. Blood pressure control with valsartan and hydrochlorothiazide in clinical practice: The MACHT Observational Study. Blood Press 2006;15 Suppl 1:27-32.
22. Hermida R. C., Caho C., Ayala D. E. et al. Administration time-dependent effects of valsartan on ambulatory blood pressure in hypertensive subjects. Hypertension 2003;42:283-290.
23. Calvo C., Hermida R. C., Ayala D. E, Ruilope L. M. Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension. J Hypertens 2004;22:837-846.
24. Fogari R., Zoppi A., Mugellini A. et al. Comparative efficacy of losartan and valsartan in mild-to-moderate hypertension: Results of 24-hour ambulatory blood pressure monitoring. Cur Ther Res 1999;60:195-206.
25. Fogari R., Mugellini A., Zoppi A. et al. A double-blind, crossover study of the antihypertensive efficacy of angiotensin II-receptor antagonists and their activation of the renin-angiotensin system. Cur Ther Res 2000;61:669-679.
26. Fogari R., Mugellini A., Zoppi A. et al. Efficacy of losartan, valsartan, and telmisartan in patients with mild to moderate hypertension: A double-blind, placebo-controlled, crossover study using ambulatory blood pressure monitoring. Cur Ther Res 2002;63:1-14.
27. Julius S., Bach D., Kjeldsen S. et al. Predictors of one year blood pressure control and treatment resistance in the VALUE trial. Am J Hypertens 2002;15:111A.
28. Julius S., Kjeldsen S., Brunner H. et al. VALUE trial: long term blood pressure trends in 13449 patients with hypertension and high cardiovascular risk. Am J Hypertens 2003;16:544-548.
29. Julius S., Kjeldsen S. E., Weber M. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004;363:2022-2031.
30. Csaika C., Buclin T., Brunner H. R., Biollaz J. Pharmacokineticpharmacodynamic profile of angiotensin II receptor antagonists. Clin Pharmacokinet 1997;32:1-29.
31. Stokes J., Kannel W. B., Wolf P. A. et al. Blood pressure as a risk factor for cardiovascular disease. The Framingham study - 30 years of follow-up. Hypertension 1989;13 Suppl.5:133-135.
32. Foote E. F., Halstenson C. E. New therapeutic agents in the management of hypertension: angiotensin II-receptor antagonists and renin inhibitors. Ann Pharmacother 1993;27:1495-1503.
33. Neutel J., Weber M., Pool J. et al.. Valsartan, anewangiotensin Ilantagonist: antihypertensive effects over 24 hours. Clin Ther 1997;19:447-458.
34. Oparil S., Dyke S., Harris F. et al. The efficacy and safety of valsartan compared with placebo in the treatment of essential hypertension. Clin Ther 1996;18:797-810.
35. Hall J., Marbury T., Gray J. et al. Long term safety, tolerability and efficacy of valsartan: results from one and two years trials. J Clin Res 1998;1:147-159.
36. Hobxerda N. J., Fogari R., Angeli P. et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and-safety compared with placebo and enalapril. J Hypertens 1996;14:1147-1151.
37. Ridker P. M., Danielson E., Rifai N., Glynn R. J. Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial. Hypertension 2006;48:73-79.
38. Ruilope L. M., Malacco E., Khder Y. et al. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. Clin Ther 2005;27:578-587.
39. Griin A., Francillon A., Bodin F. et al. A comparison of the efficacy and tolerability of a new angiotensin II antagonist, valsartan, with enalapril in patients with mild-to-moderate essential hypertension [abstract]. Eur Heart J 1995;16 Suppl.:61.
40. Black H. R., Graff A., Shute D. et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension. Efficacy, tolerabilty and safety compared to an angiotensin converting enzyme inhibitor lisinopril (protocol 50). Novartis 1997.
41. Valsartan: long term efficacy and tolerability compared to lisinopril in elderly patients with essential hypertension (protocol 28). Novartis 1996.
42. Oddou-Stock P., Gallin M., Kobi P. et al. Comparison of the efficacy of two angiotensin II antagonists, valsartan and losartan, in essential hypertension [abstract]. Am J Hypertens 1997;10:84A.
43. Ridker P. M., Danielson E., Rifai N., Glynn R. J. Valsartan, Blood Pressure Reduction, and C-Reactive Protein Primary Report of the Val-MARC Trial. Hypertension 2006;48:73-79.
44. Benz J., Black H, Graff A. et al. Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. J Hum Hypertens 1998;12:861-866.
45. Kjeldsen S. E., Julius S., Brunner H. et al. Characteristics of 15, 314 hypertensive patients at high coronary risk. The VALUE trial. The Valsartan Antihypertensive Long-term use Evaluation. Blood Press 2001;10:83-91.
46. Weycker D., Edelsberg J., Vincze G. et al. Risk of diabetes in a real-world setting among patients initiating antihypertensive therapy with valsartan or amlodipine. J Hum Hypertens 2007;21:374-380.
47. Weycker D., Fahey H., Edelsberg J., Oster J. Risk of diabetes in hypertensive patients receiving valsartan versus losartan. J Clin Hypertens 2007; Suppl A: 448.
48. Viberti G., Wheeldon N. M. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002;106:672-678.
49. Uzu T., Sawaguchi M., Maegawa H., Kashiwagi A. Reduction of microalbuminuria in patients with type 2 diabetes: the Shiga Microalbuminuria Reduction Trial (SMART). Diabetes Care 2007;30:1581-1583.
50. Dahlof B. Valsartan and the renin-angiotensin-aldosterone system: blood pressure control and beyond. J Renin Angiotensin Aldosterone Syst 2000;1(2 Suppl):14-16.
51. Bedigian M. P. Improving the prognosis of diabetic patients: evaluating the role of intensive versus moderate blood pressure control with selective angiotensin II receptor blocker (ARB) therapy. J Renin Angiotensin Aldosterone Syst 2000;1(2 Suppl):25-28.
52. Hollenberg N. K., Parving H. H., Viberti G et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens 2007;25:1921-1926.
53. Smith D. G., Nguyen A. B., Peak C. N., Frech F. H. Markov modeling analysis of health and economic outcomes of therapy with valsartan versus amlodipine in patients with type 2 diabetes and microalbuminuria. J Manag Care Pharm 2004;10:26-32.
54. The NAVIGATOR Study Group. Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events. N Engl J Med 2010;362:1477-1490.
55. Remuzzi A., Gagliardini E., Donadoni C. et al. Effect of angiotensin II antagonism on the regression of kidney disease in the rat. Kidney Int 2002;62:885-894.
56. Remuzzi G., Perico N., Macia M., Ruggenenti P. The role of reninangiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int Suppl 2005;99:57-65.
57. Blantz R. C., Gabbai F. B. Effect of angiotensin II on glomerular hemodynamics and ultrafiltration coefficient. Kidney Int Suppl 1987;20:108-111.
58. Lapinski R., Perico N., Remuzzi A. et al. Angiotensin II modulates glomerular capillary permselectivity in rat isolated perfused kidney. J Am Soc Nephrol 1996;7:653-660.
59. Ruiz-Ortega M., Lorenzo O., Suzuki Y. et al. Proinflammatory actions of angiotensin II. Curr Opin Nephrol Hypertens 2001;10:321-329.
60. Mezzano SA., Ruiz-Ortega M., Egido J. Angiotensin II and renal fibrosis. Hypertension 2001;38:635-638.
61. Brenner B. M. Hemodynamically mediated glomerular injury and the progressive nature of kidney disease. Kidney Int 1983;23:647-655.
62. Tepel M., van der Giet M., Zidek W. Efficacy and Tolerability of Angiotensin II Type 1 Receptor Antagonists in Dialysis Patients Using AN69 Dialysis Membranes. Kidney Blood Press Res 2001;24; 71-74.
63. Cohn J. N., Tognoni G, for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-1675.
64. Maggioni A., Anand I., Gottlieb S. et al. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensinconverting enzyme inhibitors. J Am Coll Cardiol 2002;40:1414-1421.
65. Cohn J., Anand I., Latini R. et al. Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure. Circulation 2003;108:61-64.
66. Wong M., Staszewsky L., Latini R. et al. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. J Am Coll Cardiol 2002;40:970-975.
67. Schmieder R., Hua T. Reduced Incidence of New Onset Atrial Fibrillation with Angiotensin II Receptor Blockade: The VALUE-Trial. J Hypertens 2006;24(Suppl):3.
68. Julius S., Kjeldsen S. E., Brunner H. et al. VALUE trial: Long-term blood pressure trends in 13, 449 patients with hypertension and high cardiovascular risk. Am J Hypertens 2003;16:544-548.
69. Julius S., Kjeldsen S. E., Weber M. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-2031.
70. Julius S., Weber M. A., Kjeldsen S. E. et al. The Valsartan Antihypertensive Long-Term use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. Hypertension 2006;48:385-391.
71. Maggioni A. P., Latini R., Carson P. E. et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005;149:548-557.
72. Mutlu H., Scedil I. M. et al. The Efficacy of Valsartan in Essential Hypertension and its Effects on Left Ventricular Hypertrophy. Blood Pressure 2002;11:53-55.
73. Thurmann PA., Kenedi P., Schmidt A. et al. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1998;98:2037-2042.
74. Jackson T. K., Garrison J. C. The Pharmacological Basis of Therapeutics. 9th Ed. Eds J. G. Hardman et al., New York 1996:733-758.
75. http://www.cardiosite.ru/articles/article.asp?id=1381
76. http://medi.ru/doc/271507.htm
77. Knudsen S. T., Andersen N. H., Poulsen S. H. et al. Pulse pressure lowering effect of dual blockade with candesartan and lisinopril vs. high-dose ACE inhibition in hypertensive type 2 diabetic subjects: a CALM II study posthoc analysis. Am J Hypertens 2008;21:172-176.
78. Mogensen C. E., Neldam S., Tikkanen I. et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Br Mtd J 2000;321:1440-1444.
79. Mann J. F. E., Schmieder R. E., McQueen M. et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008;372:547-53.
80. Casas J. P., Chua W., Loukogeorgakis S. et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005;366:2026-2033.
81. Hegner G., Faust G., Freytag F. et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared to hydrochlorothiazide. Eur J Clin Pharmacol 1997;52:173-177.
82. Benz J., Oshrain C., Henry D. et al. Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide. J Clin Phannacol 1997;37:101-107.
83. Holwerda N. J., Fogari R., Angeli P. et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. J Hypertens 1996;14:1147-1151.
84. Bloom B. S. Continuation of initial antihypertensive medication after I year of therapy. Clin Ther 1998;20:671-681.